title: [Evaluation of the specific delayed cutaneous hypersensitivity response(DTCH) after specific active immunotherapy (SAI) using autologous tumor cells in patients operated upon for renal carcinoma].
abstract: From Dec 1986 to Dec 1990, 113 consecutive patients radically resected for renal cell carcinoma, have been randomized after surgery to observation or to Active Specific Immunotherapy (A.S.I.). 43 patients stage I-II and 13 p. stage III, according to TNM entered the treatment arm consisting of 10 autologous irradiated tumor cells injected intradermally, either mixed with BCG 10(7) (on days 28th and 35th after surgery) or alone (on day 42th). At randomization and 1, 6 and 12 months after treatment, patients were evaluated for the development of a DTCH to autologous tumor and to autologous normal cells, obtained by mechanical and enzymatic dissociation of the surgical specimens. Baseline DTCH were negative in all patients. One month after completing A.S.I. 36 out of 50 evaluable patients displayed a significant DTCH response to autologous tumor, which remained positive in 23/40 patients at 6 months. Our data clearly indicate that Active Specific Immunotherapy with autologous tumor cells mixed with BCG can elicit a specific immune response to autochthonous tumor as measured by DTCH.
authors.affiliation: Gruppo Oncologico Clinico Cooperativo del nord-est (GOCCNE), Centro di Riferimento Oncologico, Aviano.
authors.forename: M
authors.initials: M
authors.lastname: Francini
authors.forename: E
authors.initials: E
authors.lastname: Galligioni
authors.forename: A
authors.initials: A
authors.lastname: Carbone
authors.forename: M G
authors.initials: MG
authors.lastname: Trovò
authors.forename: D
authors.initials: D
authors.lastname: Di Donna
authors.forename: A
authors.initials: A
authors.lastname: Merlo
authors.forename: V
authors.initials: V
authors.lastname: Dal Bo
authors.forename: M
authors.initials: M
authors.lastname: Quaia
authors.forename: A
authors.initials: A
authors.lastname: Spada
authors.forename: D
authors.initials: D
authors.lastname: Crivellari
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000627:therapeutic use; D002277:Carcinoma / Q000276:immunology* / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000209:etiology*; D007117:Immunization, Secondary; D016233:Immunotherapy, Active; D007271:Injections, Intradermal; D007680:Kidney Neoplasms / Q000276:immunology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D014411:Neoplastic Stem Cells / Q000276:immunology* / Q000528:radiation effects; D009392:Nephrectomy
chemical_list: D001500:BCG Vaccine
vernacular_title: Valutazione della risposta cutanea di ipersensibilità ritardata specifica (DTCH) dopo immunoterapa attiva specifica (ASI) con cellule tumorali autologhe in pazienti operati di carcinoma renale.